Invokana (canagliflozin) is one of several “new generation” type 2 diabetes drugs known as SGLT2 inhibitors approved on March 29, 2013 by U.S Food and Drugs Administration. The drug inhibits normal kidney function to allow patients to pass excess blood glucose through urination. It is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Janssen also markets Invokamet, a combination of canagliflozin and metformin. Invokana is associated with several life-threatening complications includes Diabetic Ketoacidosis or Acidosis, Kidney Failure, Heart Attack , Urinary Tract Infections, Blood Infection and Bone Fractures. As per the response came from 9 pooled clinical trial Canagliflozin increases the risk of fracture. The clinical trial found that the incidence rates of bone fractures in elderly patients who took canagliflozin for more than 85 weeks was 1.1 in the comparator group, 1.4 for those on 100 mg of canagliflozin and 1.5 for those on 300 mg of canagliflozin. They suffered losses in bone mineral density in their hips and lower spines.
The U.S. Food and Drug Administration revises the drug’s warning label to include an increased risk for bone fractures and increased risk for reduced bone mineral density. The information about the risk for bone fractures was already included in the adverse reactions section of the labels for Invokana and Invokamet. After the recent trials which confirmed the potential link between Invokana and increased risk for bone fractures and increased risk for reduced bone mineral density revised the drug label and added a new warning and precaution. The U.S. Food and Drug Administration strengthened warning for Invokana also include fractures can occur as early as 12 weeks after initiating treatment. FDA suggested patient should talk to their health care professionals about factors that may increase their risk for bone fracture and not to stop or change their diabetes medicines without first consulting to their health care professional. Doing so can lead to uncontrolled blood sugar levels that can be harmful.
The increase risk of bone fractures with other drugs in the Sodium glucose transporter 2 (SGLT2) inhibitors, including Farxiga (dapagliflozin) Xigduo XR (dapagliflozin and metformin extended-release) Invokamet (canagliflozin and metformin) Jardiance (empagliflozin) and Glyxambi (empagliflozin and linagliptin) is constantly evaluated by the FDA to figure out if additional label changes or studies are needed. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of Invokana medication. It will help FDA for further investigations as well as in clinical trials. The drug’s manufacturer Janssen Pharmaceuticals, a subsidiary of corporate giant Johnson & Johnson, actively defended its product and failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious and life threatening medical complications associated with Invokana.
Any patient who was prescribed Invokana and suffered from Bone Fractures and reduced bone mineral density, Contact Drugsclaim.com. You may be entitled to compensation by filing a suit and our lawyers can help. The Drugsclaim Lawyers and Attorneys are investigating claims that Invokana may be linked to kidney failure, cardiovascular complications, Foot and Leg Amputation and bone fractures. We have an experience team of Invokana injury lawyers to handle and evaluate the claim. They are prepared to help you and your family gets the compensation you deserve and that is free of cost till we win your case.